Antony, France, 8 July 2014 - STALLERGENES S.A. (Euronext Paris), a global healthcare company specialized in the diagnosis and treatment of allergies with allergen immunotherapy, today welcomed Fleur Pellerin, Secretary of State for Foreign Trade, the Promotion of Tourism and French Nationals Abroad to its principal site in Antony, Hauts-de-Seine, France.

During this visit, Fleur Pellerin announced the creation of the "Export + Health & Cosmetics" programme, supported and financed by the General Investment Commission (Commissariat Général à l'Investissement - CGI), and implemented by UBIFRANCE as part of the Investment for the Future Programme.  Its purpose is to accelerate the growth of SMEs in the Medical Devices, Drugs and Cosmetics sectors in their registration procedures in 5 countries (Brazil, China, the United States, India and Russia) by advising them on market approaches, safeguarding their procedures concerning certification and providing financial assistance for the registration of their products.

Stallergenes, an international development model

Stallergenes is a medium-sized French company which has managed to expand substantially at an international level. As such, the company has over the past 3 years doubled its number of locations around the world, with the figure now standing at 20. The Group is is expanding outside Europe, particularly in Russia, Australia, Argentina, Turkey and the Middle East.

On 1 April 2014, Stallergenes obtained approval from the US Food and Drug Administration (FDA) for its latest innovation, ORALAIR®, the first immunotherapy tablet to treat grass pollen allergy to be registered in this country.

A pioneer for more than 50 years in personalized medicine in the allergy field and world leader in allergen immunotherapy, Stallergenes now markets its treatments in 75 countries from its main site in Antony.

 "Fleur Pellerin's visit is a very positive sign of the interest shown in our company and more generally in our industry, both strongly geared towards export. The future of the French healthcare industries will largely be built beyond our borders, notably in high potential markets such as the US, Russia, China and Latin America, in which Stallergenes has already gained footholds. These international developments must be supported by France's public authorities, who also have a duty not to weaken our businesses in their domestic market," said Christian Chavy, STALLERGENES Chief Executive Officer.

distributed by